INT144481

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 2007
Last Reported 2010
Negated 4
Speculated 0
Reported most in Body
Documents 55
Total Number 59
Disease Relevance 50.40
Pain Relevance 4.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SERPING1) extracellular region (SERPING1)
Anatomy Link Frequency
plasma 18
blood vessels 1
body 1
SERPING1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 578 98.56 Very High Very High Very High
imagery 2 95.76 Very High Very High Very High
abdominal pain 51 94.80 High High
antagonist 140 94.48 High High
Pain 143 94.08 High High
Inflammation 42 92.12 High High
cva 13 88.52 High High
Pain management 8 65.44 Quite High
corticosteroid 29 59.28 Quite High
Antihistamine 58 56.24 Quite High
Disease Link Frequency Relevance Heat
Hereditary Angioedema 3219 100.00 Very High Very High Very High
Pressure And Volume Under Development 1495 99.84 Very High Very High Very High
Targeted Disruption 58 99.84 Very High Very High Very High
Lymphatic System Cancer 32 99.46 Very High Very High Very High
Disease 284 99.20 Very High Very High Very High
Laryngeal Edema 249 99.20 Very High Very High Very High
Hepatitis C Virus Infection 11 99.08 Very High Very High Very High
Edema 204 99.04 Very High Very High Very High
Hypersensitivity 75 98.98 Very High Very High Very High
Death 50 98.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Even if effective androgen doses in HAE do not require a measurable increase of C1-INH in plasma, it is still possible that these drugs relay on C1-INH production and their efficacy is less when C1-INH catabolism is very rapid [38].
Gene_expression (production) of C1-INH in plasma
1) Confidence 0.77 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 0.99 Pain Relevance 0
Recombinant C1-INH, conestat alfa, Rhucin® is recombinant human C1-INH produced in transgenic rabbit milk [6,28].
Gene_expression (produced) of C1-INH associated with targeted disruption
2) Confidence 0.77 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921362 Disease Relevance 0.34 Pain Relevance 0.03
Recombinant C1-INH, conestat alfa, Rhucin® is recombinant human C1-INH produced in transgenic rabbit milk [6,28].
Gene_expression (produced) of C1-INH associated with targeted disruption
3) Confidence 0.77 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921362 Disease Relevance 0.34 Pain Relevance 0.03
None of the studies using either Lev’s or CSL Behring’s products have found any evidence of viral seroconversion with C1-INH concentrate infusions; however, earlier studies before viral inactivation procedures demonstrated HCV transmission secondary to C1-INH from Immuno produced C1-INH (Cicardi et al 1995).
Gene_expression (produced) of C1-INH associated with hepatitis c virus infection
4) Confidence 0.75 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.63 Pain Relevance 0
Furthermore, new treatment modalities that have recently been developed are presented: novel molecules targeting bradykinin, either by inhibiting its generation from plasma kininogens or by direct inhibition of its specific receptors on blood vessels, replacement therapy with human recombinant C1-INH produced in transgenic rabbits.
Gene_expression (produced) of C1-INH in blood vessels associated with targeted disruption and bradykinin
5) Confidence 0.75 Published 2009 Journal Harefuah Section Abstract Doc Link 19899257 Disease Relevance 1.04 Pain Relevance 0.18
People with HAE have defective C1 INH synthesis with typical C1 INH levels that are 5%-30% of normal.2 Bradykinin is generated in large quantities via the contact pathway once C1 INH is depleted (Figure 1)[2].
Gene_expression (synthesis) of C1 INH associated with hereditary angioedema and bradykinin
6) Confidence 0.75 Published 2010 Journal J Cardiothorac Surg Section Body Doc Link PMC2965712 Disease Relevance 1.56 Pain Relevance 0.23
The condition is the result of a defect in the gene controlling the synthesis of C1-inhibitor, which regulates the activity of a number of plasma cascade systems.
Gene_expression (synthesis) of C1-inhibitor in plasma
7) Confidence 0.71 Published 2008 Journal Clin Mol Allergy Section Abstract Doc Link PMC2374835 Disease Relevance 0.79 Pain Relevance 0.15
Relevant exclusion criteria included a history of hypersensitivity to C1-INH concentrate, acquired angioedema due to C1-INH deficiency, all other types of angioedema not associated with C1-INH deficiency, use of any C1-INH concentrate within 24 h before the start of treatment in I.M.P.A.C.T.2, and use of fresh frozen plasma or native plasma within 7 days before the start of treatment.


Gene_expression (deficiency) of C1-INH in plasma associated with pressure and volume under development and hypersensitivity
8) Confidence 0.67 Published 2010 Journal J Clin Immunol Section Body Doc Link PMC2970824 Disease Relevance 0.50 Pain Relevance 0
We reserve plasma-derived C1-INH infusions for on-demand treatment of severe angioedema events and do not use this for prophylaxis.


Gene_expression (infusions) of C1-INH in plasma associated with pressure and volume under development
9) Confidence 0.67 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 0.59 Pain Relevance 0
Autoantibody-mediated AAE seemed to be, at the beginning, a new type of AAE in which autoreactive immunoglobulins, instead of lymphoma tissues, was the cause of C1-INH depletion [20].
Gene_expression (depletion) of C1-INH associated with pressure and volume under development and lymphatic system cancer
10) Confidence 0.67 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.77 Pain Relevance 0
The pathogenesis of the acquired defect of C1 inhibitor and the associated disease
Gene_expression (defect) of C1 inhibitor associated with disease
11) Confidence 0.67 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.86 Pain Relevance 0.13
This product is made by the introduction of a human C1-INH gene into rabbits.
Gene_expression (introduction) of C1-INH
12) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.63 Pain Relevance 0
In many countries C1-INH is used for the treatment of acute HAE attacks; however, C1-INH is not yet approved in some countries, including the US.
Gene_expression (used) of C1-INH associated with hereditary angioedema
13) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.87 Pain Relevance 0
In many countries C1-INH is used for the treatment of acute HAE attacks; however, C1-INH is not yet approved in some countries, including the US.
Neg (not) Gene_expression (approved) of C1-INH associated with hereditary angioedema
14) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.80 Pain Relevance 0
One of the main C1-INH products is Berinert P®, and the company that produces it claims that over 100 million units of Berinert P® have been administered with no proven cases of viral transmission (Juers and Groner 2004).
Gene_expression (products) of C1-INH
15) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.61 Pain Relevance 0
Gadek et al demonstrated that C1-INH levels peaked rapidly and dropped quickly; however, C4 levels peaked approximately 6 hours after the C1-INH levels, and the C4 levels remained elevated for a much longer period of time.
Gene_expression (levels) of C1-INH
16) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.57 Pain Relevance 0
One such product is a recombinant human C1-INH (rhC1-INH) (Rhucin®; Pharming, Leiden, The Netherlands).
Gene_expression (product) of C1-INH
17) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.70 Pain Relevance 0
However, the study by Levi et al (2006) does indeed demonstrate improvement in symptoms with this interval, suggesting that even increasing C1-INH levels slightly can result in significant reduction of HAE attacks.
Gene_expression (levels) of C1-INH associated with hereditary angioedema
18) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.23 Pain Relevance 0
Decreased levels of C1-INH are believed to allow increased activation of the kallikrein cascade leading to an increase in bradykinin as a mechanism of angioedema.
Gene_expression (levels) of C1-INH associated with pressure and volume under development and bradykinin
19) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.76 Pain Relevance 0.08
C1-INH and C4 levels were measured after plasma infusion.
Gene_expression (levels) of C1-INH in plasma
20) Confidence 0.65 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox